foxo4-dri senolytic animal model 2023 2024 Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment FOXO4-DRI part 1 , #peptide
FOXO4 DRI part 1 , #peptide #molecule #research #health #information Targeting the FOXO4 p53 axis by retro inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedeberg's Archives of Pharmacology Springer Nature Link Senotherapy for chronic lung disease ScienceDirect The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $5.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


